Financial Results Presentation Materials for the Fiscal Year Ending March 2026 | KISSEI PHARMACEUTICAL CO.,LTD. (4547) timely disclosure

Worth reading

58In focus

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

9075

¥ million (year-on-year increase in net sales)

Wording

Conditional

How definitive the wording is.

Contents of this document

Financial results presentationFiscal year ended March 2026 (fiscal 2025)11 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales¥97,406 million+10.3%

Operating profit¥-2,927 million

Ordinary income¥-1,162 million

Net income¥13,779 million+15.2%

Gross Profit Margin47 %

Operating profit margin-3 %

Selling, general and administrative expenses¥48,745 million

Full-year earnings forecast

Fiscal Period CoveredFiscal year ending March 2027

Net Sales

¥95,700 million

Operating profit

¥4,400 million

Ordinary income

¥6,000 million

Net income for the current fiscal year

¥14,500 million

Research and development costs

¥16,500 million

What the company explained in this material

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Net Sales

Pharmaceuticals business sales2,651

Domestic pharmaceuticals3,788

Overseas Licensing-1,078

Healthcare foods-59

Sales from Other businesses6,424

Net income for the current fiscal year

Gross profit1,753

Research and development costs-9,632

Other SG&A expenses-822

Non-Operating Income and Expenses563

Extraordinary Gains and Losses9,417

Income Taxes537

New initiatives

Domestic launch of Iselty for the treatment of uterine fibroids
In-licensing of technology for Veligrotug and Elegrobart
Commencement of clinical trials for KSP-0914, KSP-0576 and KSP-0930
Licensing agreement for the development and marketing rights to olutasidenib in Taiwan
Renewal of the Core Information System
Construction of the new formulation building at the Matsumoto Plant and the Central Headquarters Building, and consolidation of Tokyo head office offices
Acquisition and disposal of treasury shares

Key KPIsA metric the company considers important as a management benchmark.

ROE6.3 %
EPS¥331.54
Cross-shareholdings as a percentage of net assets14 %
Clinical development programs9 Projects
Domestic pharmaceutical sales¥67,764 million
Year on year against the same period last year+5.9%
Iselty sales in Europe (Q4/2025)3,766 Thousands of dollars

Segment results

Pharmaceuticals Business

Net Sales

¥77,950 million

Year on year against the same period last year+3.5%

Domestic pharmaceuticals

Net Sales

¥67,764 million

Year on year against the same period last year+5.9%

Overseas Licensing

Net Sales

¥6,691 million

Year on year against the same period last year-13.9%

Healthcare foods

Net Sales

¥3,494 million

Year on year against the same period last year-1.7%

Other Businesses

Net Sales

¥19,455 million

Year on year against the same period last year+49.3%

Medium-term management plan targets

Plan nameBeyond 80

Target fiscal yearFiscal 2029

ROE8% or higher

Net Sales¥110 billion or higher

Operating profit before R&D expensesOperating profit before R&D expenses of ¥29 billion or higher

Capital AdequacyLess than ¥200 billion in equity

EPS¥400 or higher

Cross-shareholdings as a percentage of net assets10% or lower

Clinical development programs10 or more projects

Financial targets

ROE

Actual results6.3%

Target8% or higher

Capital Adequacy

Actual results¥230.1 billion

TargetLess than ¥200 billion in equity

Cross-shareholdings as a percentage of net assets

Actual results14.0%

Target10% or lower

Market Size / Share

Female population in Japan (aged 20–54)25 million women in Japan (aged 20–54)

Women with uterine fibroids7.5 million women with uterine fibroids

Women requiring treatment2.5 million women requiring treatment

Annual patient visits274,000 annual patients

Capital expenditures

¥94 100 million

Annual Dividend

Fiscal year ending March 2026 forecast¥170 per share

Breakdown

Regular dividend¥130

Commemorative dividend¥40

Payout ratio

Target40% or more

Fiscal year ending March 2026 forecast89.0%

Total payout ratio86.0%

Acquisition of treasury shares

Actual results for the fiscal year ending March 2026

¥5.2 billion

Number of Shares1.37 million shares

Forecast for the fiscal year ending March 2027

¥6 billion

Number of Shares1.3 million shares

Contents of this document
Item	Details
Document type	Financial results presentation
Fiscal Period Covered	Fiscal year ended March 2026 (fiscal 2025)
Net Sales	¥97,406 million (YoY +10.3%)
Operating profit	¥-2,927 million
Ordinary income	¥-1,162 million
Net income	¥13,779 million (YoY +15.2%)
Gross Profit Margin	47 %
Operating profit margin	-3 %
Selling, general and administrative expenses	¥48,745 million
Full-year earnings forecast	Fiscal Period Covered Fiscal year ending March 2027 / Net Sales ¥95,700 million / Operating profit ¥4,400 million / Ordinary income ¥6,000 million / Net income for the current fiscal year ¥14,500 million / Research and development costs ¥16,500 million
Segment results	Pharmaceuticals Business Net Sales ¥77,950 million / yoy_pct 3.5 / Domestic pharmaceuticals Net Sales ¥67,764 million / yoy_pct 5.9 / Overseas Licensing Net Sales ¥6,691 million / yoy_pct -13.9 / Healthcare foods Net Sales ¥3,494 million / yoy_pct -1.7 / Other Businesses Net Sales ¥19,455 million / yoy_pct 49.3
Breakdown of Factors Affecting the Change	Net Sales Pharmaceuticals business sales 2,651 / Domestic pharmaceuticals 3,788 / Overseas Licensing -1,078 / Healthcare foods -59 / Sales from Other businesses 6,424 / Net income for the current fiscal year Gross profit 1,753 / Research and development costs -9,632 / Other SG&A expenses -822 / Non-Operating Income and Expenses 563 / Extraordinary Gains and Losses 9,417 / Income Taxes 537
Key KPIs	Indicator name ROE / Value 6.3 % / Year on year against the same period last year Not disclosed, Indicator name EPS / Value ¥331.54 / Year on year against the same period last year Not disclosed, Indicator name Cross-shareholdings as a percentage of net assets / Value 14 % / Year on year against the same period last year Not disclosed, Indicator name Clinical development programs / Value 9 Projects / Year on year against the same period last year Not disclosed, Indicator name Domestic pharmaceutical sales / Value ¥67,764 million / Year on year against the same period last year ¥5.9 million, Indicator name Iselty sales in Europe (Q4/2025) / Value 3,766 Thousands of dollars / Year on year against the same period last year Not disclosed
Medium-term management plan targets	Plan name Beyond 80 / Target fiscal year Fiscal 2029 / ROE 8% or higher / Net Sales ¥110 billion or higher / Operating profit before R&D expenses Operating profit before R&D expenses of ¥29 billion or higher / Capital Adequacy Less than ¥200 billion in equity / EPS ¥400 or higher / Cross-shareholdings as a percentage of net assets 10% or lower / Clinical development programs 10 or more projects
Financial targets	ROE Actual results 6.3% / Target 8% or higher / Capital Adequacy Actual results ¥230.1 billion / Target Less than ¥200 billion in equity / Cross-shareholdings as a percentage of net assets Actual results 14.0% / Target 10% or lower
Annual Dividend	Fiscal year ending March 2026 forecast ¥170 per share / Breakdown Regular dividend ¥130 / Commemorative dividend ¥40
Payout ratio	Target 40% or more / Fiscal year ending March 2026 forecast 89.0% / Total payout ratio 86.0%
Acquisition of treasury shares	Actual results for the fiscal year ending March 2026 Amount ¥5.2 billion / Number of Shares 1.37 million shares / Forecast for the fiscal year ending March 2027 Amount ¥6 billion / Number of Shares 1.3 million shares
Capital expenditures	¥94 100 million
Market Size / Share	Female population in Japan (aged 20–54) 25 million women in Japan (aged 20–54) / Women with uterine fibroids 7.5 million women with uterine fibroids / Women requiring treatment 2.5 million women requiring treatment / Annual patient visits 274,000 annual patients
New initiatives	Domestic launch of Iselty for the treatment of uterine fibroids, In-licensing of technology for Veligrotug and Elegrobart, Commencement of clinical trials for KSP-0914, KSP-0576 and KSP-0930, Licensing agreement for the development and marketing rights to olutasidenib in Taiwan, Renewal of the Core Information System, Construction of the new formulation building at the Matsumoto Plant and the Central Headquarters Building, and consolidation of Tokyo head office offices, Acquisition and disposal of treasury shares

Items this document does not state (10)

Results for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

In the fiscal year ended March 2026, higher sales in the Pharmaceuticals business and Other businesses, growth in domestic pharmaceuticals, and orders for GIGA School projects contributed to the increase in sales. The operating loss and ordinary loss resulted from higher SG&A expenses, primarily research and development expenses related to the in-licensing of technology for TED therapeutic drugs and the advancement of development programs. The increase in net income was supported by gains on the sale of investment securities and a decrease in impairment losses. For the fiscal year ending March 2027, the company expects sales to decline due to a pullback in GIGA School projects in the Information Services business, while forecasting a return to operating and ordinary profitability as the cost of sales ratio improves and SG&A expenses decline due to the year-on-year pullback in research and development expenses.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.